Agenus Inc

Most Recent

  • uploads///martha dominguez de gouveia gPTpdumc unsplash
    Company & Industry Overviews

    Agenus: Attractive Entry Level after Recent Pullback

    This year, Agenus (AGEN) stock has fluctuated widely. The clinical-stage biotechnology company’s stock fell from $3.88 in February to about $2.12 in August.

    By Oleksandr Pylypenko
  • uploads///AdobeStock_
    Healthcare

    Will Genocea Stock Bounce Back? In-Depth Analysis

    Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.

    By Oleksandr Pylypenko
  • uploads///Graph
    Company & Industry Overviews

    Incyte Advances R&D Strategy with Multiple Partnerships

    In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN).

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Who Is Incyte Collaborating With?

    Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Profit Taking in XBI Holdings Pulled the Fund Down

    The SPDR S&P Biotech ETF (XBI) fell by 1.1% to close at $51.72 and was trading above the 20-day moving average price of $48.7.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.